Furthermore, our results unveiled an additive effect of combination of solamargine and metformin in the inhibition of p65, MUC1 and prostate cancer cell growth, implying the potential new role and molecular mechanism in combination of solamargine and metformin in controlling CRPC cell growth. Here, MUC1 is linked to prostate carcinoma.